Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Janet Pope Janetbirdope
3 years 1 month ago
Get the skinny on Bimmy! Gotta learn this name #Bimekizumab in bio naive PsA N=852 Bimmy=IL17 A & F inhibitor Great data on skin & joints. Where will it fit in as we have other IL17Ai’s is IL17F giving added value? #ACR22 #ACRBest @RheumNow https://t.co/wNAzTaLhsM
Aurelie Najm AurelieRheumo
3 years 1 month ago
800+ women w/ IMID & 1700+ ctrl w/ 6 yrs follow-up
All GC users < BMD levels
-4.2% > 2.5mg/d
-2.7% <2.5mg/d
Crude FX rate 4.8/100PY GC >= 5mg/d, 2.5/100PY GC < 2.5mg/d
🦴Fx incidence > IMID vs. Ctrls
GC use >= 5mg/d x2 risk of Fx
https://t.co/6sj77PwyYQ
Abs#L01 #ACR22 @Rheumnow https://t.co/OZhfuh0Jrm
There has been a lot of talk lately about the difference in the way male and female PsA patients experience their disease. Are the differences only cultural or are there important clinical differences in the disease presentation, organ involvement and complications that physicians should be aware of?
Eric Dein ericdeinmd
3 years 1 month ago
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴
Reminder: Recalculate FRAX scores with scaling for prednisone equivalent dosing!
Use other clinical fracture risk assessments
@RheumNow https://t.co/qZDlb1Cij7
TheDaoIndex KDAO2011
3 years 1 month ago
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines:
FRAX needs to be adjusted according to the dose of GC's (7.5+ mg/day multiply FRAX score by 1.2)
#ACR22 @rheumnow https://t.co/U7IOjbTwxN
Olga Petryna DrPetryna
3 years 1 month ago
#L01 #acr22 @rheumnow chronic GC use in rheum Dx assoctd w/⬇️ T scores & ⬆️fracture even if dose 2.5 mg or less. GC use ≥5 mg/day associated w/ 2-fold higher risk of fracture of any kind compared to all other doses& controls (aHR 2.37, 95% CI 1.33-4.23).Preventable w/anti-OP Rx https://t.co/sCWkEBPMMT
Richard Conway RichardPAConway
3 years 1 month ago
Almayali et al. Follow-up of GLORIA study. Now tapering of the pred 5mg after 2 years. Small increase in disease activity (to same level as prev placebo), numerical increase in flare. No adrenal insufficiency @RheumNow #ACR22 Abstr#2000 https://t.co/5oclSdlXWA https://t.co/HT2pmsxPiC
Richard Conway RichardPAConway
3 years 1 month ago
Wow! Walrabenstein et al. RCT of plant-based diet (and exercise and stress management) vs usual care in low-moderate disease activity RA. It worked! But which of the 3 parts of the intervention was responsible? @RheumNow #ACR22 Abstr#1998 https://t.co/X1f07ZWPjU https://t.co/nkM4misfFW
Richard Conway RichardPAConway
3 years 1 month ago
Yokose et al. Higher risk of mortality in women with gout. Primarily CVD related death. @RheumNow #ACR22 Abstr#1757 https://t.co/Ft3Km8Jw17 https://t.co/uBOUnV4n0Z
Richard Conway RichardPAConway
3 years 1 month ago
Haibel et al. Intraarticular morphine no different to placebo and inferior to steroid in knee OA. @RheumNow #ACR22 Abstr#1833 https://t.co/9dOlfYMVlj https://t.co/a3uvw3gVw3
Richard Conway RichardPAConway
3 years 1 month ago
Kivitz et al. Phase 2 RCT Dazodalibep (non-antibody biologic antagonist of CD40L) in csDMARD/bDMARD-IR RA. Improve DAS28-CRP, CDAI, SDAI, TJC, SJC at day 113. @RheumNow #ACR22 Abstr#2008 https://t.co/RwRbeFC4rt https://t.co/F8bEI1lZGM
Eric Dein ericdeinmd
3 years 1 month ago
L09 #ACR22 MTX in Post-Roe Era
6% patients reported barrier to MTX access
1 pt noted restriction to HCQ
Most delays due to pharmacy - told due to pregnancy/abortion concerns or unexplained reason
Rare BUT Real Problem - shows importance of @ACRheumDC advocacy efforts
@RheumNow https://t.co/8Yr7nynzN6
Eric Dein ericdeinmd
3 years 1 month ago
L10 #ACR22 Efgartigimod in IMNM
IgG1 Fc fragment targeting neonatal Fc receptor (FcRn)
Restored grip and muscle strength in mice studies with pathogenic anti-HMGCR+ (p<0.05)
Total IgG and anti-HMGCR Ab became undetectable
@RheumNow
For lupus, sedentary lifestyle may be a driving force of disease activity. Today, the final day of ACR, Sarah Patterson, MD from UCSF will present oral abstract #2225 entitled “Physical Inactivity is Associated with Increased Expressi
Richard Conway RichardPAConway
3 years 1 month ago
Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-analysis of CARES trial. @RheumNow #ACR22 Abstr#1809 https://t.co/I6evAl4BLd https://t.co/n70FvYah1p
Poster Hall